Bank of America heads into the back half of May with shorts quietly retreating and the Street holding firm — yet the stock itself keeps sliding, creating a gap worth watching.
The price tells the awkward part of the story. BAC closed at $49.77 on Friday, down 3% on the week and nearly 7% lower over the past month. The RSI has dropped to 37.6, pushing into oversold territory. The stock is now trading more than 20% below the consensus analyst target of roughly $63 — a gap that implies either a compelling buying opportunity or stale Street optimism. The broader bank peer group moved in the same direction, with USB, ZION, and TFC each falling 4–4.6% on the week. WFC dropped close to 3%. JPM and held better, each off less than 2% — suggesting BAC is underperforming its closer peer set even in a weak tape for the sector.
The short-interest picture, however, tells a less aggressive story than the price action implies. Short interest has fallen sharply — down nearly 12% on the week and close to 18% over the past month — settling at just 1.2% of the free float. That is not a meaningful short position for a $350 billion bank. The borrow market reflects the same comfort level: cost to borrow is a negligible 0.34%, and while availability has tightened this week relative to earlier in the month, it remains consistent with a liquid, heavily traded large-cap name. The ORTEX short score is stable at 30, well below any threshold that would flag rising short pressure. Sellers are not piling in here through the lending market.
Options positioning has eased modestly from its more defensive posture earlier in May. The put/call ratio dipped to 1.24 on Friday, a touch below its 20-day average of 1.28 and 0.6 standard deviations below the mean. That is a mild relief versus the readings above 1.40 seen in the first half of the month. The 52-week high on PCR was 1.67 — so even the elevated May prints were far from a full defensive posture. Options traders are slightly less hedged than they were, though the ratio remains structurally put-heavy relative to its longer-run lows around 1.08.
The Street has not flinched despite the price slide. Following the Q1 print on April 15 — where the stock barely moved on the day before drifting slightly lower over the following week — multiple firms raised targets. Jefferies moved to $65, Keefe Bruyette to $64, Oppenheimer and Evercore both to $61, and Truist to $61, all maintaining positive ratings. The sole cautionary voice before earnings was JPMorgan, which trimmed its target to $57.50 from $61.50 while keeping an Overweight. The net message from analysts is clear: the bull case rests on a 7% year-on-year revenue jump to $30.3 billion, with net interest income rising 9%, strong investment banking fees, and consumer net income up 21%. The bear case centres on CET1 ratio slippage to 11.2% and macro risks around recession and asset quality. With a PE of 10.7 and price-to-book at 1.21 — the latter down roughly 8% over the past month — valuation has compressed, which analysts appear to view as an entry point rather than a warning.
Insider activity adds a gentle cautionary note. The 90-day net insider figure is nominally positive on a share-count basis, but the recent transactions are almost entirely sells. CFO-level and divisional leaders sold over $14 million combined in the past three months, led by a $6.7 million sale from Chief Risk Officer Geoffrey Greener on May 5. CEO Brian Moynihan sold shares in both April and March, though those appear linked to award vest-and-sell programs rather than discretionary exits. None of these transactions are unusual at a bank of this scale, but the absence of any insider buying against a 7% one-month price decline is worth noting.
Q2 earnings are set for July 14. With short sellers stepping back and the Street maintaining high targets, the next print becomes less about whether the revenue growth story is intact and more about whether capital ratios and macro credit indicators give analysts reason to revisit those raised targets.
See the live data behind this article on ORTEX.
Open BAC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
